Severe Acute Respiratory News and Research

RSS

Is the new bivalent COVID-19 vaccine the booster we've been waiting for?

The bivalent COVID-19 vaccine developed by GSK and Sanofi shows promising results with a 64.7% overall effectiveness against symptomatic COVID-19, according to a phase 3 trial. The vaccine performs especially well as a booster, achieving 75.9% efficacy in non-naïve subjects.

17 Sep 2023

How well do current vaccines hold up against new SARS-CoV-2 variants BA.2.86 and FLip?

The study explores the efficacy of three-dose monovalent or bivalent vaccinations in neutralizing newly emerged SARS-CoV-2 variants BA.2.86 and FLip. While BA.2.86 showed lower immune evasion abilities compared to recent XBB variants, it was less effectively neutralized by the monoclonal antibody S309, raising questions about vaccine efficacy against evolving strains.

17 Sep 2023

Phase 3 study: The efficacy of monovalent SARS-CoV-2 vaccine with AS03 adjuvant in adults

The effectiveness of a novel monovalent recombinant protein vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

15 Sep 2023

Unlocking the power of lectins: BOA emerges as a potent weapon against all SARS-CoV-2 variants

Researchers discover that antiviral lectins like BOA can effectively inhibit SARS-CoV-2 and its variants by targeting spike glycans, opening doors for potential pan-coronavirus treatments. The study reveals that BOA's multivalent interactions make it a potent inhibitor against a range of viral variants, offering promise for future therapeutic strategies.

14 Sep 2023

Past infections may shape your COVID booster's punch against Omicron

This in-depth study examines how previous immunity impacts the effectiveness of COVID-19 booster vaccinations and susceptibility to Omicron breakthrough infections. The research highlights the significant role of individual immune histories in shaping both humoral and cellular responses to SARS-CoV-2, urging for more tailored vaccine strategies.

14 Sep 2023

Impact of prior SARS-CoV-2 infection and mRNA vaccination on contagiousness and infection risk

The study finds that natural SARS-CoV-2 infection offers stronger immunity against the virus compared to mRNA vaccines. However, mRNA vaccines significantly reduce the infectiousness of individuals with COVID-19, playing a crucial role in limiting the virus's transmission.

14 Sep 2023

Utilizing deep learning to enhance the accuracy of mortality forecasts in emergency rooms

Researchers enhanced the accuracy of mortality predictions in emergency departments by employing advanced data-synthesis techniques and machine-learning models.

14 Sep 2023

COVID-19 doubles risk of early type 1 diabetes signs in high-risk children

New research in JAMA finds a temporal association between SARS-CoV-2 infections and the onset of islet autoimmunity, a precursor to type 1 diabetes, in genetically predisposed infants. The study underscores COVID-19 as a potential risk factor for the development of this form of diabetes in young children.

13 Sep 2023

New Omicron subvariant BA.2.86: A master of immune escape but not taking over yet

Researchers have isolated a new SARS-CoV-2 Omicron subvariant, BA.2.86, revealing its ability to escape neutralizing antibodies five-fold greater than its ancestor strain. Despite its enhanced immune evasion capabilities, BA.2.86 has not shown a significant difference in spread compared to other current variants.

13 Sep 2023

How COVID-19 targets the pancreas revealed

The study uncovers the role of the PLAC8 protein in making the human pancreas vulnerable to SARS-CoV-2 infection, leading to pancreatic injury and complications in severe COVID-19 cases. The findings open up new avenues for understanding how the virus affects multiple organ systems and offer a potential target for future treatments.

12 Sep 2023

Many 'mild' COVID patients still battling lung damage a year later

A recent PLoS ONE study reveals that severe COVID-19 patients are at higher risk of long-term pulmonary impairments, with nearly half experiencing reduced lung function a year after disease onset. The study underscores the need for ongoing monitoring to manage 'long COVID' symptoms effectively.

12 Sep 2023

Is the coadministration of a COVID-19 vaccine with a seasonal influenza vaccine safe and efficacious?

Researchers investigated the comparative efficacy and safety of the simultaneous COVID-19 and seasonal influenza vaccination regimen compared to SARS-CoV-2 vaccination alone among healthcare workers who had received one or two COVID-19 booster doses.

12 Sep 2023

The safety and efficacy of the nano-based COVID-19 vaccine

A recent study evaluated the safety and efficacy of the GBP510 vaccine against SARS-CoV-2 infection.

12 Sep 2023

Vaccination amps up antibody response and cuts down COVID severity, UK study shows

UK study reveals COVID-19 vaccination effectively boosts anti-S antibody levels and reduces symptom severity post-infection, irrespective of the viral variant involved. High antibody levels are linked to quicker viral clearance, suggesting reduced transmission risk.

10 Sep 2023

Elite athletes bounce back strong: No long-term heart risks after COVID-19 recovery

The study finds that elite athletes who recovered from COVID-19 did not experience long-term negative effects on their cardiac health, allowing for the successful resumption of high-level sports. The findings also suggest that proper screening and medical counseling can pave the way for safe returns to sports post-COVID-19.

10 Sep 2023

Senolytic therapy in mild Alzheimer’s disease shows safety in phase I trial

Researchers conducted the phase 1 trial of orally-administered senolytic therapy comprising quercetin (Q) and dasatinib (D) for symptomatic and early-stage Alzheimer's disease (AD) patients.

8 Sep 2023

Onset and prognosis of post-COVID-19 condition: A 2-Year observational study

Researchers conducted a prospective cohort analysis over two years.

8 Sep 2023

Is there an association between the COVID-19 pandemic and cancer incidence?

The COVID-19 pandemic influenced cancer incidence.

8 Sep 2023

BA.2.86 Omicron variant: Is our immunity under siege?

A new preprint posted to the bioRxiv server discusses whether this variant shows neutralization escape.

7 Sep 2023

Study characterizes SARS-CoV-2 Omicron BA.2.86: New variant under watch

Researchers identify a new SARS-CoV-2 variant, BA.2.86, with enhanced ability to evade immunity but lower infectivity compared to current variants. The study highlights the need for global monitoring due to its potential to become a predominant strain if it gains infectivity through mutations.

6 Sep 2023

Severe Acute Respiratory News and Research

Is the new bivalent COVID-19 vaccine the booster we've been waiting for?

How well do current vaccines hold up against new SARS-CoV-2 variants BA.2.86 and FLip?

Phase 3 study: The efficacy of monovalent SARS-CoV-2 vaccine with AS03 adjuvant in adults

Unlocking the power of lectins: BOA emerges as a potent weapon against all SARS-CoV-2 variants

Past infections may shape your COVID booster's punch against Omicron

Impact of prior SARS-CoV-2 infection and mRNA vaccination on contagiousness and infection risk

Utilizing deep learning to enhance the accuracy of mortality forecasts in emergency rooms

COVID-19 doubles risk of early type 1 diabetes signs in high-risk children

New Omicron subvariant BA.2.86: A master of immune escape but not taking over yet

How COVID-19 targets the pancreas revealed

Many 'mild' COVID patients still battling lung damage a year later

Is the coadministration of a COVID-19 vaccine with a seasonal influenza vaccine safe and efficacious?

The safety and efficacy of the nano-based COVID-19 vaccine

Vaccination amps up antibody response and cuts down COVID severity, UK study shows

Elite athletes bounce back strong: No long-term heart risks after COVID-19 recovery

Senolytic therapy in mild Alzheimer’s disease shows safety in phase I trial

Onset and prognosis of post-COVID-19 condition: A 2-Year observational study

Is there an association between the COVID-19 pandemic and cancer incidence?

BA.2.86 Omicron variant: Is our immunity under siege?

Study characterizes SARS-CoV-2 Omicron BA.2.86: New variant under watch

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News